SLC5A2 and myocardial infarction: Unfortunately, none of the included studies in the present meta-analysis reported the use of antiplatelet therapy as co-medication, so whether SGLT2 inhibitors reduce myocardial infarct size additionally to ADP receptor antagonists still needs to be elucidated.